-
公开(公告)号：US20200172610A1
公开(公告)日：2020-06-04
申请号：US16697310
申请日：2019-11-27
发明人： Tomoyuki IGAWA , Atsuhiko Maeda , Kenta Haraya , Tatsuhiko Tachibana , Yuki Iwayanagi , Yuji Hori , Genki Nakamura , Masaru Muraoka
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
-
公开(公告)号：US09969800B2
公开(公告)日：2018-05-15
申请号：US15015287
申请日：2016-02-04
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Genki Nakamura , Masaru Muraoka
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/18 , C07K16/2866 , C07K16/36 , C07K16/40 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/6854 , G01N2500/04
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
-
公开(公告)号：US11180548B2
公开(公告)日：2021-11-23
申请号：US16697310
申请日：2019-11-27
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Kenta Haraya , Tatsuhiko Tachibana , Yuki Iwayanagi , Yuji Hori , Genki Nakamura , Masaru Muraoka
IPC分类号： A61K39/00 , C07K16/24 , C07K16/36 , C07K16/18 , C07K16/28 , C07K16/40 , C07K16/42 , G01N33/68
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
-
4.发明申请Antibodies Comprising an Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, IL-8-Binding Antibodies, and Uses Thereof 有权抗体包含离子浓度依赖性抗原结合结构域，Fc区变体，IL-8-结合抗体及其用途公开(公告)号：US20160229908A1
公开(公告)日：2016-08-11
申请号：US15015287
申请日：2016-02-04
发明人： Tomoyuki IGAWA , Atsuhiko Maeda , Kenta Haraya , Tatsuhiko Tachibana , Yuki Iwayanagi , Yuji Hori , Genki Nakamura , Masaru Muraoka
CPC分类号： C07K16/244 , A61K2039/505 , C07K16/18 , C07K16/2866 , C07K16/36 , C07K16/40 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/6854 , G01N2500/04
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
摘要翻译： 一个非排他性的方面提供了可以以离子浓度依赖性方式结合抗原的抗体进一步改进的分子。 替代的非排他性方面提供了与预先存在的ADA的结合减少的安全和更有利的Fc区变体。 替代的非排他性方面提供了优于药物的新型IL-8抗体。
-
公开(公告)号：US10519229B2
公开(公告)日：2019-12-31
申请号：US15976288
申请日：2018-05-10
发明人： Tomoyuki Igawa , Atsuhiko Maeda , Kenta Haraya , Tatsuhiko Tachibana , Yuki Iwayanagi , Yuji Hori , Genki Nakamura , Masaru Muraoka
IPC分类号： C12N15/12 , C12N15/13 , C07K16/24 , C07K16/18 , C07K16/28 , C07K16/42 , C07K16/36 , A61K39/00
摘要： One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
-
-
-
-
搜索结果
5 条记录 (耗时 0.026 秒)
